Triple-positive profile may flag adverse prostate cancer pathology - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Triple-positive profile may flag adverse prostate cancer pathology

A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.

  • By

  • Andrea Surnit

  • September 8, 2026

  • 4 min

Share

  • 1

    A combination of prostate-specific antigen density, mpMRI, and PSMA PET/CT may identify patients with adverse prostate cancer pathology.

  • 2

    In a study of 413 patients, 60% exhibited adverse pathology at radical prostatectomy.

  • 3

    The triple-positive profile showed 100% specificity and positive predictive value, but low sensitivity at 9%.

  • 4

    The study suggests this profile could guide future studies on biopsy-sparing diagnostic pathways.

  • 5

    The findings highlight the need for external validation before adopting these criteria in prospective studies.

Original Source(s)

Triple-positive profile may flag adverse prostate cancer pathology

  • by Andrea Surnit

  • September 8, 2026

Related Content

Can Proteomics Refine Lung Screening?

Proteomic biomarkers improve short-term lung cancer risk assessment.

FDA expands essential thrombocythemia care

Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.

FDA Approves Treg Cell Therapy

A randomized clinical trial found higher chronic GVHD-free survival and lower rates of serious chronic GVHD compared with standard transplantation in adults with blood cancers.